The Role of TREM2 in Alzheimer’s Disease and Other Neurological Disorders
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Late-onset AD (LOAD), is the most common form of Alzheimer's disease, representing about >95% of cases and early-onset AD represents <5% of cases. Several risk factors have been discovered that are associated with AD, with advancing age being the most prominent. Other environmental risk factors include diabetes mellitus, level of physical activity, educational status, hypertension and head injury. The most well known genetic risk factor for LOAD is inheritance of the apolipoprotein (apo) E4 allele. Recently, rare variants of TREM2 have been reported as a significant risk factor for LOAD, comparable to inheritance of apoE4. In this review we will focus on the role(s) of TREM2 in AD as well as in other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2×
“Furthermore, neurofibrillary tangle deposition correlates better with the degree of dementia, compared to the amyloid plaque burden [2].”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“This is important as numerous studies have shown that increases of ptau in CSF correlates with neuronal loss and is predictive of cognitive decline in AD [50-52].”
BackgroundBouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
TREMs in the immune system and beyond
Colonna, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1106 · Cited by 701
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688 · cited 4×
“Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, et al. (2010) LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice.”
BackgroundInfluentialRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639
CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571 · cited 4×
“It has been speculated that impaired CSF1R mediated microglial repair of axonal degeneration is the mechanism underlying HDLS [71,72].”
BackgroundInfluentialRole of toll-like receptor signalling in A uptake and clearance
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493 · cited 1×
“TLR4 deficient mice displayed increases of diffuse Aβ and fibrillar Aβ deposits compared with control mice [36], suggesting that TLR4 signaling is involved in Aβ clearance [37].”
BackgroundA role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475 · cited 1×
“TREM2 interacts with endogenous ligands on neurons, leading to the direct removal of damaged cells [45].”
BackgroundKitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473
Alzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460
Hamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440 · cited 4×
“Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, et al. (2010) LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice.”
BackgroundInfluentialHampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · cited 1×
“This is important as numerous studies have shown that increases of ptau in CSF correlates with neuronal loss and is predictive of cognitive decline in AD [50–52].”
BackgroundTREM and TREM-like receptors in inflammation and disease
Ford, J. W., & McVicar, D. W. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.009 · Cited by 434
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414 · cited 1×
“In several models of multiple sclerosis increased microglial expression of TREM2 has been shown to enhance phagocytosis and promotes a M2-like activation state of microglia, which is thought to have protective effects [46–48].”
BackgroundRayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374
Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296 · cited 2×
“Inhibition of γ-secretase produces an accumulation of TREM2 carboxyl terminal fragments at the cell surface, trapping its adaptor DAP12, and resulting in impairment of TREM2 signaling [57].”
BackgroundLPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice
Lee, D. C., Rizer, J., Selenica, M.-L. B., Reid, P., Kraft, C., Johnson, A., Blair, L., Gordon, M. N., Dickey, C. A., & Morgan, D. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-56 · Cited by 293 · cited 1×
“In addition, TLRs can affect tau related pathology; TLR4 ligand (LPS)-induced MAPT hyperphosphorylation and exacerbation of tau pathology has been well documented [41-44].”
BackgroundBlockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis
Piccio, L., Buonsanti, C., Mariani, M., Cella, M., Gilfillan, S., Cross, A. H., Colonna, M., & Panina‐Bordignon, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200636837 · Cited by 284 · cited 1×
“In several models of multiple sclerosis increased microglial expression of TREM2 has been shown to enhance phagocytosis and promotes a M2-like activation state of microglia, which is thought to have protective effects [46–48].”
BackgroundFrackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., & Wang, K. C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227813 · Cited by 276
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265
The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2
Klünemann, H. H., Ridha, B. H., Magy, L., Wherrett, J. R., Hemelsoet, D. M., Keen, R. W., De Bleecker, J. L., Rossor, M. N., Marienhagen, J., Klein, H. E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000160304.00003.ca · Cited by 254
Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225
Wisniewski, H. M., Wegiel, J., Wang, K. C., & Lach, B. (1992) · Acta Neuropathologica · doi:10.1007/bf00311383 · Cited by 221
Di Marco, L. Y., Marzo, A., Muñoz-Ruiz, M., Ikram, M. A., Kivipelto, M., Ruefenacht, D., Venneri, A., Soininen, H., Wanke, I., Ventikos, Y. A., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132225 · Cited by 215 · cited 1×
“Some of the known environmental risk factors for LOAD include diabetes mellitus, level of physical activity, educational status, hypertension and head injury [10].”
BackgroundVariant TREM2 as Risk Factor for Alzheimer's Disease
Neumann, H., & Daly, M. J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1213157 · Cited by 177 · cited 3×
“When the bacteria bind to TREM2 on macrophages, activation of the signaling pathway triggers the phagocytic uptake of the bacteria and the release of reactive oxygen species [23].”
BackgroundScholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166 · cited 2×
“We have shown that the administration of the TLR9 agonist CpG oligonucleotides (ODN) containing unmethylated CpG sequences to AD model Tg2576 mice induced a reduction of cortical and vascular Aβ levels without apparent toxicity and improve cognitive function [40].”
BackgroundSessa, G., Podini, P., Mariani, M., Meroni, A., Spreafico, R., Sinigaglia, F., Colonna, M., Panina, P., & Meldolesi, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03729.x · Cited by 165 · cited 1×
“In addition to its role as part of the innate immune systems response to pathogens, TREM2 is known to have anti-inflammatory properties; it suppresses inflammatory responses by repression of cytokine production and secretion [32].”
BackgroundGiraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene
Soragna, D. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.825-a · Cited by 75
The innate immune system in Alzheimer's disease
Boutajangout, A., & Wisniewski, T. (2013) · International Journal of Cell Biology · doi:10.1155/2013/576383 · Cited by 69 · cited 5×
“TREM2 is an innate immune receptor expressed on the cell surface of microglia, macrophages, osteoclasts and immature dendritic cells [12-14].”
BackgroundInfluentialLee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57 · cited 2×
“addition, TLRs can affect tau related pathology; TLR4 ligand (LPS)-induced MAPT hyperphosphorylation and exacerbation of tau pathology has been well documented [41–44].”
BackgroundEvidence of Trem2 Variant Associated with Triple Risk of Alzheimer’s Disease
Abduljaleel, Z., Al-Allaf, F. A., Khan, W., Athar, M., Shahzad, N., Taher, M. M., Elrobh, M., Alanazi, M. S., & El-Huneidi, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092648 · Cited by 54 · cited 1×
“Molecular dynamics simulations have suggested that the R27H substitution could have significant effects on ligand binding affinity, as well as the structural configuration of TREM2 [56].”
Background
Cited by
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET
Sandiego, C. M., Gallezot, J.-D., Pittman, B., Nabulsi, N., Lim, K., Lin, S.-F., Matuskey, D., Lee, J.-Y., O’Connor, K. C., Huang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511003112 · Cited by 356
“, minocycline (56) and TREM-2 agents (57)] and permit the assessment of novel antiinflammatory compounds to determine an optimal dose, based on the dose-dependent reductions in LPS-induced microglial activation.”
BackgroundLymphatic drainage system of the brain: A novel target for intervention of neurological diseases
Sun, B.-L., Wang, L.-H., Yang, T., Sun, J.-Y., Mao, L.-L., Yang, M.-F., Yuan, H., Colvin, R. A., & Yang, X.-Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.007 · Cited by 255
Beckmann, N., Giorgetti, E., Neuhaus, A., Zurbruegg, S., Accart, N., Smith, P., Perdoux, J., Perrot, L., Nash, M., Desrayaud, S., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0510-8 · Cited by 131
“Deficiency in TREM2 leads to Nasu-Hakola disease and patients with partial loss-of-function mutations in CSF1R suffer from hereditary diffuse leukoencephalopathy with spheroids (see reviews [34, 53]).”
Metadata
- Authors
- Yaghmoor, F.
- Venue
- Journal of Alzheimer's Disease & Parkinsonism
- Publisher
- OMICS Publishing Group
- Published
- 2014
- Volume
- 04
- Issue
- 05
- ISSN
- 2161-0460 (ISSN-L)
- OpenAlex
- W2071055552
- Cited by
- 47
- References
- 38
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.